abstract |
Novel compositions comprising a selective serotonin re-uptake inhibitor (SSRI), particularly sertraline, and a selective inhibitor for the binding of serotonin at the 5HT 2A site. The invention relates to the use of such compositions for treating or preventing mood disorders including depression and anxiety disorders. |